Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Phase 1/2 Unknown 40 enrolled Chongqing Precision Biotech Co., Ltd

NaSingle-groupOpen-labelTreatment

Summary

This is a single arm study to evaluate the efficacy and safety of CD19-targeted CAR-T cells therapy for patients with relapsed/refractory CD19+ B Cell Leukemia and Lymphoma.

Timeline

Start: 2019-12-01
Primary completion: 2023-12-31
Completion: 2024-07-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CD19 CAR-T cells	Cell therapy	—	Intravenous

Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Summary

Timeline

Drugs

Indications